Novagali Pharma Announces the Registration of its "document de base" With the French Securities Market Authority ("Autorité des marchés financiers" - AMF)

Evry, France (ots/PRNewswire) - In preparation for the application
for the listing of its shares on Eurolist by Euronext, Novagali
Pharma, an emerging ophthalmic pharmaceutical company, announces that
its document de base was registered on July 18, 2007 by the Autorité
des marchés financiers (AMF) under number I.07-132.

The document de base is available free of charge from Novagali
Pharma, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, 91000 Evry,
France, on the AMF website (www.amf-france.org) and on the Novagali
Pharma website (www.novagali.com).

The public attention is drawn to the chapter 4 of the document
de base, entitled 'Risk Factors'.

This communication is not intended to be used, and cannot be used,
by the recipient or any other person for the purpose of avoiding
United States federal tax penalties that may be imposed on the
recipient or such other person. In addition, if any United States
federal tax advice contained in this communication is used or
referred to in promoting, marketing or recommending any corporation,
partnership or other entity, investment plan, concept, structure or
arrangement (which should be assumed to be the case by a recipient or
other person who is not our client with respect to the subject matter
of the communication), then (i) such tax advice should be construed
as written to support the promotion or marketing of the transactions
or matters addressed by the advice and (ii) the recipient or other
person should seek advice based on the recipient or other person's
particular circumstances from an independent tax advisor. For further
information, please go to
http://www.shearman.com/disclaimer/tax_disclosure.html

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an emerging ophthalmic pharmaceutical company
based in the Génopôle biocluster in Evry (France), that develops
innovative products for all segments of the eye. Thanks to its
proprietary technology platforms Novasorb(R) and Eyeject(R), the
company has developed a broad pipeline of 8 innovative products
addressing main ocular conditions as well as orphan diseases. Most
advanced products include Vekacia(R), an orphan product for treatment
of vernal keratoconjunctivitis, Cationorm(R), a CE mark product for
dry eye relief, and Nova22007, a product for the treatment of
moderate-to-severe dry eye syndrome. Founded in 2000, Novagali Pharma
has raised a total amount of Euro 44 million in 3 series of
financing.

ots Originaltext: Novagali Pharma
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Press contacts: Novagali Pharma, Geneviève Garrigos,
+33-1-69-87-40-20 / +33-6-65-54-60-19,
genevieve.garrigos@novagali.com; Euro RSCG, Estelle Griffe,
+33-1-58-47-95-25 / +33-6-23-75-09-23, estelle.griffe@eurorscg.fr